Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Assets (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Assets for 9 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • Quarterly Assets fell 16.69% to $1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, down 16.69% year-over-year, with the annual reading at $1.1 billion for FY2025, 16.69% down from the prior year.
  • Assets for Q4 2025 was $1.1 billion at Denali Therapeutics, up from $1.1 billion in the prior quarter.
  • The five-year high for Assets was $1.6 billion in Q1 2024, with the low at $1.1 billion in Q3 2025.
  • Average Assets over 5 years is $1.3 billion, with a median of $1.3 billion recorded in 2022.
  • The sharpest move saw Assets skyrocketed 133.23% in 2021, then fell 27.4% in 2025.
  • Over 5 years, Assets stood at $1.4 billion in 2021, then grew by 3.99% to $1.5 billion in 2022, then decreased by 20.98% to $1.2 billion in 2023, then rose by 19.09% to $1.4 billion in 2024, then fell by 16.69% to $1.1 billion in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $1.1 billion, $1.1 billion, and $1.2 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.